跳至主要内容
临床试验/CTRI/2023/10/058236
CTRI/2023/10/058236招募中3 期

Pentoxifylline Plus Carvedilol vs Carvedilol Monotherapy in Preventing New Decompensation in Stable Cirrhotic Patients With Prior Decompensation, an Open Label Randomised Control Trial. - NI

Institute of Liver and Biliary Sciences0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
招募中

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Age 18-70 years
  • 2.Cirrhosis with prior clinical decompensation (ascites, Hepatic encephalopathy, Portal Hypertension related bleed)
  • 3.No current clinical decompensation (for at least 1 year)
  • 4.CTP A at enrollment

排除标准

  • 1. Post TIPS/ BRTO/ SAE patients
  • 2. Post renal or liver transplantation
  • 3. History of CAD, ischemic cardiomyopathy, PVD, ventricular arrythmia
  • 4. Presence of clinical ascites, HE, Jaundice
  • 5. Last clinical decompensation within 3 months
  • 6. Ongoing significant alcohol use
  • 7. Active HCV/HBV infection (Detectable HCV RNA/ HBV DNA)
  • 8. Prior Intolerance to carvedilol and hypersensitivity to Pentoxyfylline
  • 9. Use of Pentoxifylline within last 1 month
  • 10.AIH/ PBC
  • 11.Lack of informed consent
  • 12.Hepatocellular carcinoma / Portal vein thrombosis/ Budd Chiari Syndrome
  • 13.Non-cirrhotic portal hypertension
  • 14.Ongoing CAM/Hepatotoxic drug intake
  • 15.Known HIV infection
  • 16.Pregnant women
  • 17.Hepato Pulmonary Syndrome

研究者

相似试验